ClinicalTrials.gg
RecruitingNCT06592833Updated Nov 6, 2026

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

A Phase 2 interventional study of Psilocybin and Pimavanserin in Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · Icahn School of Medicine at Mount Sinai.

Planned enrollment
6th of 18
60 · median 34
Started
2025
with 1 other
Phase 2
8 of 19
4 open now
Registered
17th of 19
by date

Among the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 17th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

4 of the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.

Read the detailed description

In this study, the researchers want to probe the role of the 5-HT2A receptor in mediating the subjective effects of psilocybin. While previous studies have shown that blockage of the 5-HT2A receptor reduces the psychedelic experience in humans, an animal study revealed that blockage of the 5- HT2A receptor abolished the psychedelic effects without affecting the antidepressant response. This suggests that the pathway responsible for the antidepressant response is dissociated from the psychedelic experience pathway, which is mediated by 5-HT2A signaling.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21-80 years, any gender
  • Current primary diagnosis of Unipolar Major Depressive Disorder (MDD) without psychotic features using criteria
  • 24-item Hamilton Rating Scale for Depression (HRSD) ≥16
  • Current diagnosis of Major Depressive Episode (MDE)
  • Capable of providing and complying with study procedures
  • Currently using or agreeing to use a highly effective , if person of (such as condoms, IUD, or oral contraceptive), for duration of the study. Male participants agree to use highly effective contraception with partners of childbearing potential
  • Discontinuation of any serotonergic drug for at least 2 weeks or 5 half-lives (whichever of the two is longer) prior to psilocybin exposure

Exclusion criteria

Exclusion Criteria:

  • Any severity of substance use disorder in the last 6 months (excluding tobacco use disorder) as determined by criteria via the SCID
  • Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months
  • Use of psychedelics in the last 12 months
  • Non-medical or illicit use of ketamine in the past 12 months
  • Negative reaction after prior use of psychedelics
  • Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder
  • Severe depression as indicated by Clinical Global Impressions (CGI)-Severity score ≥ 5 at baseline
  • Significant suicidal ideation as indicated by C-SSRS > 2 in the past 6 months at time of screening
  • Suicide attempt in the past 2 years, or clinician concern that the patient poses a risk to self or others
  • Acute, severe, or unstable medical illness
  • Weight > 300 lbs., or girth size incompatible with scanner bore
  • Any conditions/qualities that make participation in MRI imaging unsafe*
  • Any physical or intellectual disability adversely affecting ability to complete assessments.
  • Current pregnancy or currently breast feeding.
  • Any abnormal lab test result, including clinically significant abnormal baseline liver and/or renal function tests
  • Currently being treated with a medication. Contraindicated medications include antipsychotic medications, serotonergic antidepressant medications, and mood stabilizers that may attenuate the effects of psilocybin. Strong inhibitors and inducers are also contraindicated. UGT1A9 and UGT1A10 inhibitors, monoamine oxidase, and aldehyde or alcohol dehydrogenase inhibitors are prohibited concomitant medications.
  • History of abnormal or QTc interval >450 ms on screening
  • Use of medications known to prolong the QT interval
  • Any congenital prolongation of the QT interval or a family history of long QT syndrome
  • A family history of sudden cardiac or unexplained death
  • A family history in a first-degree relative of psychosis/schizophrenia or related disorders
  • A first-degree family history of bipolar disorder
  • A history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication
  • A history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/torsades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome)
  • Preexisting cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension, hypertension, tachycardia, and any cardiovascular conditions that may be worsened/exacerbated by elevated blood pressure or heart rate.
  • Baseline vital sign parameters at screening and on day of dosing prior to dose that exceed to the following values for systolic blood pressure (SBP), diastolic (DBP), and heart rate (HR): SBP > 139 mmHg, DBP 89 mmHg, and HR > 90 bpm
  • to either psilocybin or pimavanserin
  • Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin
  • Positive urine toxicology at screening
  • Any clinically significant abnormalities on 12-lead (ECG)
  • (MMSE) score \< 25
  • Brief Psychiatric Rating Scale (BPRS-6) > 5
  • Potential fall risk
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Psilocybin + Pimavanserin

    single dose Psilocybin and single dose Pimavanserin

    Drug: Psilocybin · Drug: Pimavanserin

  • Placebo comparator
    Psilocybin + Placebo

    single dose Psilocybin and single dose Placebo

    Drug: Psilocybin · Drug: Placebo

Interventions

  • Psilocybin, 25mg, given once orally.

  • Pimavanserin, 34mg, given once orally

    Also known as: Nuplazid

  • DrugPlacebo

    Matching placebo.

06

What researchers measure

Primary outcomes

  1. Mystical Experience Questionnaire (MEQ-30) Score

    Acute subjective effects of psilocybin measured by the Mystical Experience Questionnaire (MEQ-30). Full Scale ranges from 0 to 150, with higher scores indicating more mystical experience.

    Time frame: 6 hours post-treatment

Secondary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS) Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) will be used to measure improvement in depressive symptoms 7 days after dosing. This 10-item clinician-rated scale measures the severity of depressive symptoms. Full scale ranges from 0 to 60, with higher scores indicating more depressive symptoms.

    Time frame: 7 days after dosing

07

Study locations

1 of 1 sites recruiting
  • Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research
    New York, New York 10025, United States
    Recruiting
    • Depression and Anxiety Center · Contactdac@mssm.edu · (212) 241-6539
    • James Murrough · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Because this study is privately funded, the research team is not required to share IPD.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2029, 49 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 49 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Mar 2028 → Mar 2029 and completion Mar 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Feb 25, 2025
Primary completionEst.
Mar 2029was Mar 2028
CompletionEst.
Apr 2029was Mar 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 1, 2028→Mar 2029
Nov 6, 2026
Study completion
Mar 1, 2028→Apr 2029
Nov 6, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedA history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/tosadestorsades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Mar 1, 2028→Mar 2029
    Study completion Mar 1, 2028→Apr 2029
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedA history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/tosadestorsades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06592833
Responsible party
James Murrough (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Sep 19, 2024
Start date
Feb 25, 2025
Primary completion
Mar 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Depression and Anxiety Center Icahn School of Medicine at Mount Sinai
Contact
dac@mssm.edu
(212) 241-6539
James Murrough
principal investigator · Icahn School of Medicine at Mount Sinai
Rachel Fremont
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimavanserin

Start the discussion